Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Catalent Inc (CTLT)

Create Alert
Create Alert
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile






Follow Catalent Inc's earnings

Delivery Method


Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
56.10 -0.20    -0.36%
06:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
7:31:51 - Real-time Data
  • Volume: 1,469,828
  • Bid/Ask: 55.96 / 58.50
  • Day's Range: 56.05 - 56.70
Type:  Equity
Market:  United States
Catalent Inc 56.10 -0.20 -0.36%

Catalent Inc Company Profile

Get an in-depth profile of Catalent Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.


Equity Type


Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Contact Information

Address 14 Schoolhouse Road
Somerset, 08873
United States
Phone 732 537 6200
Fax 732 537 6480

Top Executives

Name Age Since Title
Rolf A. Classon 78 2014 Independent Director
Jack L. Stahl 70 2014 Independent Lead Director
Gregory T. Lucier 59 2015 Independent Director
Alessandro Maselli 51 2016 President, CEO & Director
John J. Greisch 68 2018 Executive Chairman of the Board
Edward R. Robinson - 2015 Member of Advisory Board
Donald Eugene Morel 65 2015 Independent Director
Michael J. Buckley 62 2015 Member of Advisory Board
Carolyn R. Bertozzi 56 2015 Member of Scientfic & Advisory Board
Barry C. Buckland 75 2015 Member of Advisory Board
Daniel R. Marshak 66 2015 Member of Advisory Board
J. Martin Carroll 74 2015 Independent Director
Matthew R. Stober 56 - Member of the Biologics Advisory Board
Steven K. Barg 60 2023 Independent Director
David E. Schaffer 54 2019 Member of the Biologics Advisory Board
Stephanie Smith Okey 63 2023 Independent Director
Michael J. Barber 63 2021 Independent Director
Michelle R. Ryan 57 2023 Independent Director
Frank A. D'Amelio 66 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

CTLT Comments

Write your thoughts about Catalent Inc
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email